Diferencia entre revisiones de «Acanthosis nigricans»

Sin resumen de edición
Línea 1: Línea 1:
==Background==
==Background==
*Multiple forms, but malignant acanthosis nigricans is most important
*Multiple forms, but malignant acanthosis nigricans is most important
*Clinically indistinguishable from benign form
*Associated with GI and GU malignancies, which may have concomitant weight loss
*Non malignant form may be associated with endocrine abnormalities, such as insulin resistance


==Clinical Features==
==Clinical Features==
Línea 29: Línea 30:


[[Category:Dermatology]]
[[Category:Dermatology]]
Schwarzenberger K, Callen JP. Chapter 53: Dermatologic manifestations in patients with systemic disease. In: Bolognia JL,‎ Schaffer JV,‎ Cerroni L, eds. Dermatology. 4th ed. Philadelphia, PA: Elsevier; 2017:820.

Revisión del 02:23 29 mar 2023

Background

  • Multiple forms, but malignant acanthosis nigricans is most important
  • Associated with GI and GU malignancies, which may have concomitant weight loss
  • Non malignant form may be associated with endocrine abnormalities, such as insulin resistance

Clinical Features

  • Hyperpigmented, velvety
  • Plaques
  • Most commonly intertriginous areas, posterior neck
  • May have concurrent acrochordons, skin tags

Malignant Acanthosis Nigricans[1]

Malignant acanthosis nigricans secondary to ovarian cancer
  • Associated with other dermal manifestations of internal cancers
  • Most commonly associated with colonic adenocarcinoma, gastric cancer, ovarian cancer
  • Red flags:
    • Up to 50% of malignant acanthosis nigricans have oral involvement
    • Rapid appearance of lesions
    • Extensive involvement
    • Older adult
    • Unexplained weight loss
    • Lesions in atypical sites such as palms/soles, mucous membranes


See Also

References

  1. Miller JH et al. Acanthosis Nigricans Clinical Presentation. eMedicine. Dec 3, 2015. http://emedicine.medscape.com/article/1102488-clinical#showall.

Schwarzenberger K, Callen JP. Chapter 53: Dermatologic manifestations in patients with systemic disease. In: Bolognia JL,‎ Schaffer JV,‎ Cerroni L, eds. Dermatology. 4th ed. Philadelphia, PA: Elsevier; 2017:820.